Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study

Simple item page
dc.contributor.authorYu, Yongfengen_US
dc.contributor.authorZhang, Qingen_US
dc.contributor.authorZhang, Jieen_US
dc.contributor.authorLu, Shunen_US
dc.date.accessioned2020-11-18T10:07:24Z
dc.date.available2020-11-18T10:07:24Z
dc.date.issued2019-08
dc.description.abstractBackground: Pulmonary sarcomatoid carcinoma (PSC) is a rare histologic subtype of nonsmall cell lung cancer with limited targeted treatment options. In this study, we aimed to investigate the prevalence of MET ex14 skipping mutation in PSC patients without common targetable mutations in EGFR, KRAS, ALK, ROS1, and RET. Materials and Methods: In total, 46 resected specimens of PSC without these mutations were assessed for MET ex14 skipping mutation by next-generation sequencing (NGS) based on the Oncomine Focus Assay libraries. Results: Among 52 cancer-relevant genes included in the targeted NGS panel, the MET ex14 skipping mutation was the only mutation identified in our cohort, which was present in 4 (9%) of 46 patients. For patients with METex14 skipping mutation, the median overall survival (OS) was 35 months (1050 days) compared with a median OS of 27 months (807 days) for those without METex14 skipping mutation (hazard ratio [HR] = 0.59, P = 0.488). The median disease-free survival (DFS) in METex14 skipping mutation-positive patients was 18 months (540 days) compared with a median DFS of 13.6 months (408 days) for negative patients (HR = 0.76, P = 0.680). Conclusions: These findings reflect the prevalence of MET ex14 skipping mutation as up to 9% in Chinese patients with PSC negative for other common targetable mutations, allowing provision of appropriate genetic counseling and treatment in these patients. A larger population-based study is warranted to determine the clinicopathological and prognostic implications of MET ex14 skipping mutation in PSCen_US
dc.identifier.affiliationsShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, Chinaen_US
dc.identifier.affiliationsDepartment of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, Chinaen_US
dc.identifier.affiliationsDepartment of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, Chinaen_US
dc.identifier.affiliationsShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, Chinaen_US
dc.identifier.citationYu Yongfeng, Zhang Qing, Zhang Jie, Lu Shun. Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study. Journal of Cancer Research and Therapeutics. 2019 Aug; 15(4): 909-913en_US
dc.identifier.issn0973-1482
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/213452
dc.languageenen_US
dc.publisherWolters Kluwer India Pvt. Ltd.en_US
dc.relation.issuenumber4en_US
dc.relation.volume15en_US
dc.source.urihttps://dx.doi.org//10.4103/jcrt.JCRT_591_18en_US
dc.titlePrevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcrt2019v15n4p909.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Cancer Research and Therapeutics